Pegfilgrastim Maintains Relative Dose Intensity and Decreases Hospitalisations in Patients With Endometrial Cancer.

Kenro ChikazawaKen ImaiTakaki ItoAzusa KimuraK O HiroyoshiYokota MihoTomoyuki KuwataRyo Konno

Published in: In vivo (Athens, Greece) (2021)

Pegfilgrastim can maintain a dose intensity of ≥85% during chemotherapy for the treatment of gynaecologic cancers and decrease hospital-visit frequency.

Keyphrases

endometrial cancer
high intensity
chemotherapy induced
healthcare
emergency department
squamous cell carcinoma
adverse drug